Singapore markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
726.31-19.64 (-2.63%)
At close: 04:00PM EDT
723.55 -2.76 (-0.38%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close745.95
Open749.16
Bid0.00 x 1000
Ask0.00 x 1100
Day's range722.07 - 750.01
52-week range370.68 - 800.78
Volume3,486,054
Avg. volume3,050,669
Market cap690.551B
Beta (5Y monthly)0.37
PE ratio (TTM)124.80
EPS (TTM)5.82
Earnings date30 Apr 2024
Forward dividend & yield5.20 (0.70%)
Ex-dividend date14 Feb 2024
1y target est826.94
  • Yahoo Finance Video

    Weight loss drugs and the many use cases in medical treatments

    Novo Nordisk's (NVO) Ozempic and Wegouvy and Eli Lilly's (LLY) Zepbound are the leading names in the latest GLP-1 weight loss drug cycle, a trend that has seen a variety of use cases sprout up since these brand names' inceptions late last year. Yahoo Finance Health Reporter Anjalee Khemlani explains the new use cases being found for this class of drugs, including infertility treatments and even benefits for Alzheimer's patients. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Luke Carberry Mogan.

  • FX Empire

    Eli Lilly Shares Show Healthy Rise

    Eli Lilly and Company (LLY) shares are up in 2024 to the tune of 28% so far. Looking under the surface, it’s clear to see why this biopharmaceuticals stock is so powerful.

  • Zacks

    Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

    J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.